Method for treating chronic inflammatory diseases

Patent metadata

Field	Value
Publication number	US-2018344705-A1
Application number	US-201815938956-A
Country	US
Kind code	A1
Filing date	Mar 28, 2018
Priority date	Mar 31, 2009
Publication date	Dec 6, 2018
Grant date	—

Abstract

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

First claim

1 .- 35 . (canceled)

36 . A method of treating a chronic inflammatory disease, comprising administering to a subject in need thereof an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof.

37 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 100 mg/day, 200 mg/day, 400 mg/day, 800 mg/day or 1000 mg/day.

38 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 100 mg/day.

39 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day.

40 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 400 mg/day.

41 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 800 mg/day.

42 . The method according to claim 36 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 1000 mg/day.

43 . The method according to claim 36 , wherein the chronic inflammatory disease is arthritis.

44 . The method according to claim 36 , wherein the chronic inflammatory disease is rheumatoid arthritis.

45 . The method according to claim 36 , wherein the chronic inflammatory disease is osteoarthritis.

46 . The method according to claim 36 , wherein the chronic inflammatory disease is sarcoidosis.

47 . The method according to claim 36 , wherein the chronic inflammatory disease is eczematous dermatitis.

Assignees

• Ligand Pharm Inc

Inventors

• Zhang Jinkun
• Dziewanowska Zofia E
• Belder Rene
• Henderson Ian
• Bogardus Joseph B
• Zhang Zhaoying

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/02

  Immunomodulators · CPC title